Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Flockhart

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Child and Adolescent Psychiatric Clinics of North America|February 16, 2000
Cytochrome P450-mediated drug interactionsD A Flockhart, J R Oesterheld
Lancet (London, England)|January 1, 1999
Clinical pharmacology. Blue-chip technologyD A Flockhart, D J Webb
The New England Journal of Medicine|May 12, 1994
Evaluating drugs after their approval for clinical useR L Woosley, D A Flockhart
Clinical Pharmacology and Therapeutics|January 23, 2014
Personal DNA donation to energize genomic medicineW J Lu, D A Flockhart
Clinical Pharmacology and Therapeutics|March 7, 2007
Enhancing race-based prescribing precision with pharmacogenomicsA Nguyen, Z Desta, D A Flockhart
Clinical Pharmacology and Therapeutics|February 10, 1999
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)Z Desta, T Kerbusch, D A Flockhart
Journal of Clinical Pharmacology|December 1, 1999
Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolamR Yuan, D A Flockhart, J D Balian
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 26, 1999
Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6J G Shin, N Soukhova, D A Flockhart
Antimicrobial Agents and Chemotherapy|February 13, 2001
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3AZ Desta, N V Soukhova, D A Flockhart
British Journal of Clinical Pharmacology|February 13, 2001
Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidolJ G Shin, K Kane, D A Flockhart
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Child and Adolescent Psychiatric Clinics of North America|February 16, 2000
Cytochrome P450-mediated drug interactionsD A Flockhart, J R Oesterheld
Lancet (London, England)|January 1, 1999
Clinical pharmacology. Blue-chip technologyD A Flockhart, D J Webb
The New England Journal of Medicine|May 12, 1994
Evaluating drugs after their approval for clinical useR L Woosley, D A Flockhart
Clinical Pharmacology and Therapeutics|January 23, 2014
Personal DNA donation to energize genomic medicineW J Lu, D A Flockhart
Clinical Pharmacology and Therapeutics|March 7, 2007
Enhancing race-based prescribing precision with pharmacogenomicsA Nguyen, Z Desta, D A Flockhart
Clinical Pharmacology and Therapeutics|February 10, 1999
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)Z Desta, T Kerbusch, D A Flockhart
Journal of Clinical Pharmacology|December 1, 1999
Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolamR Yuan, D A Flockhart, J D Balian
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 26, 1999
Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6J G Shin, N Soukhova, D A Flockhart
Antimicrobial Agents and Chemotherapy|February 13, 2001
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3AZ Desta, N V Soukhova, D A Flockhart
British Journal of Clinical Pharmacology|February 13, 2001
Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidolJ G Shin, K Kane, D A Flockhart
Pageof 10